156 results match your criteria infliximab intravenously


One-year outcomes with ustekinumab therapy in infliximab-refractory paediatric ulcerative colitis: a multicentre prospective study.

Aliment Pharmacol Ther 2021 Apr 28. Epub 2021 Apr 28.

Division of Gastroenterology, Hepatology, and Nutrition, Department of Paediatrics and IBD Centre, SickKids Hospital, University of Toronto, Toronto, ON, Canada.

Background: The phase 3 (UNIFI) trial of ustekinumab (anti-interleukin 12/23) demonstrated efficacy even after prior biologic failure in adult ulcerative colitis (UC), but paediatric data are lacking.

Aim: To prospectively monitor efficacy and serum concentrations of ustekinumab given to children with UC refractory to other biologics.

Methods: Children with anti-TNF refractory UC initiating ustekinumab intravenously at sites of the Canadian Children IBD Network prior to 12/2019 are included. Read More

View Article and Full-Text PDF

Combination of cassette-dosing and microsampling for reduced animal usage for antibody pharmacokinetics in cynomolgus monkeys, wild-type mice, and human FcRn transgenic mice.

Pharm Res 2021 Apr 29;38(4):583-592. Epub 2021 Mar 29.

Research Division, Chugai Pharmaceutical Co. Ltd., 1-135 Komakado, Gotemba-shi, Shizuoka, 412-8513, Japan.

Purpose: The aim of this study was to develop a useful antibody PK evaluation tool using a combination of cassette-dosing and microsampling in mice and monkeys in order to reduce the number of animals used.

Methods: Cetuximab, denosumab, infliximab, and a mixture of the three antibodies, i.e. Read More

View Article and Full-Text PDF

Effectiveness and safety of infliximab in cardiac Sarcoidosis.

Int J Cardiol 2021 May 12;330:179-185. Epub 2021 Feb 12.

Department of Pulmonology, St. Antonius Hospital, Nieuwegein, Utrecht, the Netherlands; Department of Pulmonology, Utrecht University Medical Center, Utrecht, the Netherlands.

Background: Immunosuppressive therapy in active cardiac sarcoidosis (CS) might prevent potential life-threatening complications. Infliximab (IFX) is a tumor necrosis factor alpha monoclonal antibody proven to be effective in refractory extracardiac sarcoidosis. It is sparsely used in CS, because of its association with worsening heart failure in prior studies. Read More

View Article and Full-Text PDF

Maintaining infliximab induced clinical remission with azathioprine and 5-aminosalicylates in acute severe steroid-refractory ulcerative colitis has lower cost and high efficacy (MIRACLE): a multicenter study.

Intest Res 2021 Feb 3. Epub 2021 Feb 3.

Department of Gastroenterology, Dayanand Medical College, Ludhiana, India.

Background/aims: Infliximab (IFX) has been used to induce and maintain remission in patients with severe steroid-refractory ulcerative colitis (UC). Long-term use of biologics in developing countries is limited by high cost and frequent side effects. An optimal maintenance strategy in these patients needs to be established. Read More

View Article and Full-Text PDF
February 2021

[Association of Breg cells and Treg cells with the clinical effects of Infliximab in the treatment of Chinese patients with Crohn's disease].

Zhonghua Yi Xue Za Zhi 2020 Nov;100(42):3303-3308

Department of Gastroenterology, Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.

To explore the associations of regulatory B cells (Breg cells) and regulatory T cells (Treg cells) with the clinical effect of Infliximab in the treatment of Chinese patients with Crohn's disease (CD). From January 2017 to June 2019, a total of 32 CD patients at active stage and 33 age and gender-matched healthy controls were collected from the Second Affiliated Hospital of Wenzhou Medical University in this study. Approximate 5 ml of peripheral fasting venous blood was obtained from every subject. Read More

View Article and Full-Text PDF
November 2020

A man in his fifties with chronic diarrhoea and weight loss.

Tidsskr Nor Laegeforen 2020 08 14;140(11). Epub 2020 Aug 14.

Background: Watery diarrhoea coupled with weight loss is a serious condition with many potential causes. We present a possibly underappreciated cause which usually responds well to treatment; left untreated it may have a severe course.

Case Presentation: A man in his fifties with known coronary and cerebrovascular disease was admitted for watery diarrhoea. Read More

View Article and Full-Text PDF

Infliximab in young paediatric IBD patients: it is all about the dosing.

Eur J Pediatr 2020 Dec 19;179(12):1935-1944. Epub 2020 Aug 19.

Department of Paediatric Gastroenterology, Erasmus Medical Center/Sophia Children's Hospital, Rotterdam, The Netherlands.

Infliximab (IFX) is administered intravenously using weight-based dosing (5 mg/kg) in inflammatory bowel disease (IBD) patients. Our hypothesis is that especially young children need a more intensive treatment regimen than the current weight-based dose administration. We aimed to assess IFX pharmacokinetics (PK), based on existing therapeutic drug monitoring (TDM) data in IBD patients < 10 years. Read More

View Article and Full-Text PDF
December 2020

Leptin mediates improvements in cognitive function following treatment with infliximab in adults with bipolar depression.

Psychoneuroendocrinology 2020 10 20;120:104779. Epub 2020 Jun 20.

Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Institute of Medical Science, University of Toronto, Toronto, ON, Canada.

A potential role for leptin in the pathophysiology of bipolar disorder (BD) has been proposed. We recently investigated the effects of the tumor necrosis factor-alpha (TNF-α) antagonist infliximab in individuals with bipolar depression. Leptin is known to interact with the TNF-α system. Read More

View Article and Full-Text PDF
October 2020

A comparative study of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderate to severe active rheumatoid arthritis: A subgroup analysis.

Int J Rheum Dis 2020 Jul 31;23(7):876-881. Epub 2020 May 31.

Rheumatology Service, Clinical Hospital, Universidade Federal do Paraná, Curitiba, Brazil.

Aim: PF-06438179/GP1111 (PF-SZ-IFX) is a biosimilar of reference infliximab (Remicade ). This analysis compared the efficacy of PF-SZ-IFX and reference infliximab sourced from the European Union (IFX-EU) in patient subgroups from a randomized, comparative study of PF-SZ-IFX versus IFX-EU.

Methods: Patients with rheumatoid arthritis were randomized 1:1 to PF-SZ-IFX (n = 324) or IFX-EU (n = 326); study drug (3 mg/kg) was administered intravenously at weeks 0, 2, and 6, then every 8 weeks thereafter. Read More

View Article and Full-Text PDF

Crescentic IgA nephropathy after administration of human monoclonal interleukin-12/23p40 antibody in a patient with Crohn's disease: a case report.

CEN Case Rep 2020 08 25;9(3):204-209. Epub 2020 Feb 25.

Division of Nephrology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan.

Ustekinumab (UST), an interleukin (IL)-12/IL-23-blocking monoclonal antibody, is a novel therapeutic option for Crohn's disease (CD). We describe a 24-year-old man with CD who showed an abrupt decline in renal function after administration of UST. Twenty-nine months previously, the patient was diagnosed with CD, and abnormal urinalysis findings in health checkup were coincidentally found at that time. Read More

View Article and Full-Text PDF

Factors contributing to the systemic clearance of infliximab with long-term administration in Japanese patients with Crohn's disease: Analysis using population pharmacokinetics
.

Int J Clin Pharmacol Ther 2020 Feb;58(2):89-102

Objective: Crohn's disease (CD) is a chronic inflammatory gastrointestinal disease with repeated cycles of exacerbation and remission. Infliximab (IFX), a chimeric anti-TNF-α monoclonal antibody, has been widely used for the treatment of CD. However, no study in Japanese CD patients receiving continuous IFX for more than 1 year has been reported. Read More

View Article and Full-Text PDF
February 2020

Pharmacokinetic Similarity of ABP 710, a Proposed Biosimilar to Infliximab: Results From a Randomized, Single-Blind, Single-Dose, Parallel-Group Study in Healthy Subjects.

Clin Pharmacol Drug Dev 2020 02 19;9(2):246-255. Epub 2019 Oct 19.

Biosimilars, Amgen Inc., Thousand Oaks, California, USA.

This was a randomized, single-blind, single-dose, 3-arm parallel-group study. Healthy subjects were randomized to receive ABP 710 (n = 50) or infliximab reference product (RP) sourced from the United States (infliximab US; n = 50) or the European Union (infliximab EU; n = 50) 5 mg/kg intravenously over 2 hours. The primary endpoint was area under the serum concentration-time curve from time 0 extrapolated to infinity (AUC ) for the comparison of ABP 710 to infliximab US and infliximab EU. Read More

View Article and Full-Text PDF
February 2020

Towards the Oral Treatment of Ileo-Colonic Inflammatory Bowel Disease with Infliximab Tablets: Development and Validation of the Production Process.

Pharmaceutics 2019 Aug 23;11(9). Epub 2019 Aug 23.

Department of Pharmaceutical Technology and Biopharmacy, Groningen Research Institute of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.

Infliximab (IFX) is an intravenously administered monoclonal antibody antagonizing the effects of tumor necrosis factor-alpha (TNF) systemically and is efficacious in the treatment of inflammatory bowel disease (IBD). However, studies suggest that the anti-inflammatory effects result from local immunomodulation in the inflamed regions. Furthermore, topical inhibition of TNF in IBD ameliorates inflammation. Read More

View Article and Full-Text PDF

Refractory Oral Ulcer Responsive to Infliximab: A Case Report.

ORL J Otorhinolaryngol Relat Spec 2019;81(4):240-244. Epub 2019 Jun 28.

Department of Pathology and Experimental Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.

Purpose: Some oral ulcers are refractory to treatment. Recently, anti-tumor necrosis factor-alpha (anti-TNF-α) agents have been shown to induce relatively long remissions of refractory oral ulcers.

Methods: A 69-year man presented with a sore throat caused by a pharyngeal ulcer in the soft palate and subsequently repeatedly developed oropharyngolaryngeal ulcers and an ulcer in the ileocecal region. Read More

View Article and Full-Text PDF

Quantification of pulmonary disease activity in sarcoidosis measured with F-FDG PET/CT: SUVmax versus total lung glycolysis.

EJNMMI Res 2019 Jun 13;9(1):54. Epub 2019 Jun 13.

Department of Nuclear Medicine, St Antonius Hospital, Nieuwegein, the Netherlands.

Background: F-FDG PET/CT has proven to be a reliable tool for therapy monitoring in sarcoidosis. Previous PET studies investigated the SUVmax as a marker for disease activity. Total lung glycolysis (TLuG) is a new tool, quantifying the glycolysis of the entire lung. Read More

View Article and Full-Text PDF

Pediatric toxic epidermal necrolysis treated successfully with infliximab.

Pediatr Dermatol 2019 May 4;36(3):342-345. Epub 2019 Mar 4.

Departments of Dermatology, Zealand University Hospital, Roskilde, Denmark.

Successful management of toxic epidermal necrolysis (TEN) with tumor necrosis factor-α inhibitors has been described in adults. We present a case of a 7-year-old boy with infection-associated TEN, diagnosed by typical clinical and histopathological features, most likely caused by Mycoplasma pneumoniae. Treatment with a single dose of infliximab 5 mg/kg intravenously on day 5 after the onset of symptoms was followed by cessation of all blister formation over 3 days and complete resolution within a week. Read More

View Article and Full-Text PDF

Nivolumab-induced immune-mediated colitis: an ulcerative colitis look-alike-report of new cases and review of the literature.

Int J Colorectal Dis 2019 May 3;34(5):861-865. Epub 2019 Mar 3.

Gastroenterology Department, Hospital Universitari Germans Trias i Pujol, Carretera del Canyet s/n, 08916, Badalona, Catalonia, Spain.

Purpose: Nivolumab, a monoclonal antibody-targeting programmed cell death protein-1, is being increasingly used for the treatment of some advanced neoplasms. Several of its adverse effects are a result of the upregulation of T cells, with colitis as one of the most severe, and a challenging differential diagnosis with ulcerative colitis. However, few real-life clinical practice cases have been reported beyond trials. Read More

View Article and Full-Text PDF

Efficacy of Infliximab in Crohn's Disease Patients with Prior Primary-Nonresponse to Tumor Necrosis Factor Antagonists.

Dig Dis Sci 2019 07 28;64(7):1952-1958. Epub 2019 Feb 28.

Division of Gastroenterology, University of Washington, 1959 NE Pacific Street, Seattle, WA, 98195, USA.

Background: Tumor necrosis factor antagonists (TNFs) are effective for moderate-severe Crohn's disease (CD). Approximately one-third of patients have primary-nonresponse to TNFs, which is reported to predict worse response to subsequent TNF therapy. However, this is based on treatment with subcutaneously (SC) administered, fixed-dose TNFs after failure of intravenously (IV) administered, weight-based TNFs. Read More

View Article and Full-Text PDF

The use of biologic therapies in uveitis.

Rom J Ophthalmol 2018 Apr-Jun;62(2):105-113

"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.

Purpose: Non-infectious uveitis has been long controlled with the use of corticosteroids with many side effects and poor control in some cases. The purpose of this paper was to assess the different biologic agents (in this case infliximab and adalimumab) and to compare their efficacy in the treatment of uveitis.

Results: Adalimumab has been proven very successful in replacing or aiding corticosteroid therapy in different autoimmune mediated uveitis (Juvenile Idiopathic Arthritis, Rheumatoid arthritis, sarcoidosis) whereas infliximab has been used intravenously and recently intravitreally with very promising results in controlling Behcet's related uveitis. Read More

View Article and Full-Text PDF
February 2019

Intestinal paracoccidioidomycosis resembling Crohn's disease in a teenager: a case report.

J Med Case Rep 2018 Apr 30;12(1):108. Epub 2018 Apr 30.

Inflammatory Bowel Disease Research Laboratory, University of Campinas, UNICAMP, João Lopes Vieira Street, no 108, 61, Tower 2, Campinas, Sao Paulo, 13087-734, Brazil.

Background: Differential diagnosis of inflammatory bowel disease is often very challenging. Paracoccidioidomycosis is a fungal disease that can mimic manifestations of Crohn's disease.

Case Presentation: We report a case of a 13-year-old Caucasian boy with abdominal pain for 1. Read More

View Article and Full-Text PDF

Efficacy and safety of infliximab biosimilar Inflectra in severe sarcoidosis.

Respir Med 2018 May 19;138S:S7-S13. Epub 2018 Feb 19.

Interstitial Lung Diseases Center of Excellence, Department of Pulmonology, St Antonius Hospital, Nieuwegein, The Netherlands; Division of Heart&Lungs, University Medical Center, Utrecht, The Netherlands.

Background: Infliximab, a monoclonal antibody against tumor necrosis factor alpha (TNF-α) is effective third-line therapy in severe sarcoidosis. The originator product of Infliximab, Remicade, is expensive, limiting universal access. Recently, a less expensive biosimilar of infliximab, Inflectra, has become available, but the efficacy and tolerability has not been studied in sarcoidosis. Read More

View Article and Full-Text PDF

Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease.

Clin Pharmacokinet 2018 08;57(8):929-942

Department of Medicine, University of California San Diego, 9500 Gilman Drive #0956, La Jolla, CA, 92093, USA.

Infliximab was the first monoclonal antibody to be approved for the treatment of pediatric and adult patients with moderately to severely active Crohn's disease (CD) and ulcerative colitis (UC). It has been shown to induce and maintain both clinical remission and mucosal healing in pediatric and adult patients with inflammatory bowel disease (IBD) who are unresponsive or refractory to conventional therapies. The administration of infliximab is weight-based and the drug is administered intravenously. Read More

View Article and Full-Text PDF

Association of miR-146 rs2910164, miR-196a rs11614913, miR-221 rs113054794 and miR-224 rs188519172 polymorphisms with anti-TNF treatment response in a Greek population with Crohn's disease.

World J Gastrointest Pharmacol Ther 2017 Nov;8(4):193-200

Laboratory of Biology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.

Aim: To investigate the correlation between rs2910164, rs11 614913, rs113054794, and rs188519172 polymorphisms and response to anti-TNF treatment in patients with Crohn's disease (CD).

Methods: One hundred seven patients with CD based on standard clinical, endoscopic, radiological, and pathological criteria were included in the study. They all received infliximab or adalimumab intravenously or subcutaneously at standard induction doses as per international guidelines. Read More

View Article and Full-Text PDF
November 2017

The efficacy of infliximab combined with surgical treatment of fistulizing perianal Crohn's disease: Comparative analysis according to fistula subtypes.

Asian J Surg 2018 Sep 26;41(5):438-447. Epub 2017 Aug 26.

Division of Colon and Rectal Surgery, Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea.

Background/objective: Infliximab is regarded as an effective therapeutic to treat Crohn's disease. This study aimed to assess the efficacy of infliximab combined with surgery and to analyze clinical manifestations according to fistula subtypes in patients with fistulizing perianal Crohn's disease.

Methods: From April 2013 to December 2015, 47 patients with perianal Crohn's disease in two hospitals of South Korea (Goo Hospital, Gangnam Severance Hospital) were evaluated retrospectively. Read More

View Article and Full-Text PDF
September 2018

Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease.

Biol Blood Marrow Transplant 2017 Sep 8;23(9):1478-1484. Epub 2017 May 8.

Division of Hematology, Mayo Clinic, Rochester, Minnesota. Electronic address:

Acute graft-versus-host disease (aGVHD) is the leading cause of morbidity and mortality after allogenic hematopoietic cell transplantation (HCT). Corticosteroids are the first-line treatment; however, less than one-half of patients achieve durable remission. Studies suggest that TNF-α, a cytokine released from the bone marrow during conditioning, is involved in the pathogenesis of aGVHD. Read More

View Article and Full-Text PDF
September 2017

Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients.

Arthritis Rheumatol 2017 03;69(3):668-675

Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Marqués de Valdecilla (IDIVAL), and University of Cantabria, Santander, Spain.

Objective: To assess the efficacy of tocilizumab (TCZ) for the treatment of juvenile idiopathic arthritis (JIA)-associated uveitis.

Methods: We conducted a multicenter study of patients with JIA-associated uveitis that was refractory to conventional immunosuppressive drugs and anti-tumor necrosis factor (anti-TNF) agents.

Results: We assessed 25 patients (21 female; 47 affected eyes) with a mean ± SD age of 18. Read More

View Article and Full-Text PDF

A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study.

Br J Dermatol 2017 Mar 2;176(3):624-633. Epub 2017 Feb 2.

Department of Dermatology, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.

Background: There are currently no independent data available comparing infliximab and etanercept for the treatment of psoriasis.

Objectives: To compare these biologics without funding from pharmaceutical companies.

Methods: Overall, 50 patients were randomized to etanercept (n = 23) 50 mg subcutaneously twice weekly or infliximab (n = 25) 5 mg kg intravenously at week 0, 2, 6, 14 and 22. Read More

View Article and Full-Text PDF

Fecal Microbiota Transplantation in Recurrent NAP1/B1/027 Clostridium Difficile Infection (CDI) Resistant to Vancomycin and Metronidazole in a Patient with Ulcerative Colitis (UC): A Case Report.

Rev Med Chir Soc Med Nat Iasi 2016 Jul-Sep;120(3):563-7

Most of the studies showed that IBD patients inflammatory bowel diseases (IBD) with CDI have more of the whole range of short- and long-term worst outcomes than those without CDI. Initial infection with the BI/NAP1/027 epidemic clone was found to be a significant risk factor for relapse. However, current literature is suggesting increasingly that for patients with infections that fail to resolve with traditional antibiotic regimens, FMAT's average cure rate of >90%. Read More

View Article and Full-Text PDF
November 2018

Autologous Adipose-Derived Mesenchymal Stromal Cells for the Treatment of Psoriasis Vulgaris and Psoriatic Arthritis: A Case Report.

Cell Transplant 2016 11;25(11):2063-2069

Cellular Therapeutics Center, Makati Medical Center, Makati City, Metro Manila, Philippines.

Psoriasis is a dermatologic disease of immune origins with no definitive cure. We report the Makati Medical Center experience of utilizing autologous mesenchymal stromal cells (MSCs) for one patient with psoriasis vulgaris (PV) and another with psoriatic arthritis (PA). Patients were educated and gave informed consent, according to the principles of the Declaration of Helsinki. Read More

View Article and Full-Text PDF
November 2016

The Effects of Infliximab on Laminin, NFκB, and Anti-TNF Expression through Its Effect on Ischemic Liver Tissue.

Gastroenterol Res Pract 2016 7;2016:1738430. Epub 2016 Apr 7.

School of Medicine, Department of Hematology, Recep Tayyip Erdoğan University, 53100 Rize, Turkey.

The aim of this study was to investigate the possible protective effects of infliximab on expression of laminin, anti-TNF, and NFκB in the rat hepatic cells after ischemia/reperfusion (I/R). A total of 30 male Wistar albino rats were divided into three groups: Control (C), sham I/R (ISC), and I/R+ infliximab (ISC inf); each group comprised 10 animals. C group animals underwent laparotomy without I/R injury. Read More

View Article and Full-Text PDF